Partner at the BIO International Convention to meet with over 90% of these companies face to face Company
BIO One-on-One Partnering Webpage(s)†
Abbott
Company Partnering Webpage(s) Click
*
Company Areas of Interest Webpage(s)‡ Click
Abbvie
Click
Click
Click
Actavis
Click
Click
Click
Actelion
Click
Click
Click
Click
Click
Allergan Amgen
Click
Click
Click
Astellas
Click
Click
AstraZeneca
Click
Click Click Click
Baxter
Click
Click
Click
Bayer
Click Click Click Click Click
Click Click Click
Click
Click Click
Click
Biogen Idec Boehringer Ingelheim
Click
Click
†Requires login to partnering site (i.e. you must be registered for partnering for the event) ‡Specific to partnering if available, otherwise specific to R&D *Company is registered for partnering at BIO 2014 and has not finalized their profile. Check back for updates!
Company
Bristol-Myers Squibb
Company Partnering Webpage(s) Click
Celgene
Click
Chugai
BIO One-on-One Partnering Webpage(s)† Click Click Click
Company Areas of Interest Webpage(s)‡ Click Click
Click
Click
CSL
Click
Click
Click
Daiichi Sankyo
Click
Click
Click
Dainippon Sumitomo/ Sunovion Eisai
Click
Click
Click
Click
Click
Click
Eli Lilly
Click
Click
Click
EMD Serono
Click
Click
Click
Endo
Click
Click
Click
Forest
Click
Click
Click
Fresenius
Click
Click
Click
Galderma
Click
Click
Click
Genentech
Click
Click
Click
Gilead
Click
Click
Click
GlaxoSmithKline
Click
Click
Click
Click
Click
*
Click
Johnson & Johnson
Click Click Click
Click
Click
Kyowa Hakko Kirin
Click
Click
Click
Lundbeck
Click
Click
Click
Mallinckrodt
Click
Click
Click
Menarini
Click
Click
Merck & Co
Click
Mitsubishi Tanabe
Click
Click Click Click Click Click
Mylan
Click
Novartis
Click
*
Novo Nordisk
Click
Click
Click Click Click
Ono
Click
Click
Click
Otsuka
Click
Click
Click
Pfizer
Click Click Click
Click
Purdue
Click Click Click
Ranbaxy
Click
Click
Click
Regeneron
Click
Click
Click
Roche
Click
Click
Sanofi
Click
Click Click Click Click
Grifols IPSEN
Click Click Click
Click
Click
†Requires login to partnering site (i.e. you must be registered for partnering for the event) ‡Specific to partnering if available, otherwise specific to R&D *Company is registered for partnering at BIO 2014 and has not finalized their profile. Check back for updates!
Company
Click
Company Areas of Interest Webpage(s)‡ Click
Click
Click
Click
Click
Sinopharm
Click Click Click
Solvay
Click
Click
Servier
Company Partnering Webpage(s) Click
Shionogi Shire
Stada
BIO One-on-One Partnering Webpage(s)†
Click
Click
Takeda
Click
Click
Click
Teva
Click
Click
Click
UCB
Click
Click
Click
Valeant
Click
Click
Click
What do large pharma and biotech companies want to buy? Out-licensors are always asking this fundamental question: what do in-licensors want? “In-licensors” extend far beyond the top 50 companies. At BIO 2013, there were about 1000 drug R&D companies. Approximately 20% were in-licensors and 80% were out-licensors, according to their BIO One-on-One Partnering profiles. According to Thomson Reuters Recap, there were a little over 700 licensing and joint venture deals in 2013, involving about 500 buy-siders/licensees. For more on buy-side deal trends, see our recorded webinar with Recap. There are two great ways to figure out what the buyers want: 1) check out their partnering and “areas of interest” pages on their website 2) look at their profile in BIO’s One-on-One Partnering System, which often has great up-to-the-minute supplementary information to #1, especially for specific divisions or countries. Access to BIO’s One-on-One Partnering System requires a login based on BIO meeting attendance. For convenience, I assembled a list of the partnering and “areas of interest” webpages for the top 50 companies, along with the respective BIO One-on-One Partnering webpages. Yes, there are actually more than 50 companies in this list. Since there are different definitions of the ‘top 50’ companies, I took companies from Thomson Reuters Recap, IMS Consulting Group, Current Partnering and even Wikipedia top 50 lists and threw them all in. Enjoy, and I hope to see you at BIO. Sougato Das Director, Partnering The Biotechnology Industry Organization (BIO)
†Requires login to partnering site (i.e. you must be registered for partnering for the event) ‡Specific to partnering if available, otherwise specific to R&D *Company is registered for partnering at BIO 2014 and has not finalized their profile. Check back for updates!
*Company is registered for partnering at BIO 2014 and has not finalized their profile. .... took companies from Thomson Reuters Recap, IMS Consulting Group, ...
What do large pharma and biotech companies want to buy? ... of interestâ pages on their website 2) look at their profile in BIO's One-on-One Partnering System,.
The Value of Bioscience Innovation in Growing Jobs and Improving .... of Health, NIH Awards by Location & Organization (summary information within RePORT.
Feb 1, 2013 - next generation of biofuels and other renewable energy sources in order to reduce climate change and dependence on fossil fuels, while still ...
Feb 1, 2013 - next generation of biofuels and other renewable energy sources in order to reduce ... 2 Peter Gwynne and Gary Heebner, Drug Discovery and ...
Iowa's bioscience industry is sizable, specialized and diverse in its employment concentration, and has grown significantly since 2012. The state's bioscience ...
Oct 20, 2015 - companies and explore potential partnerships and business collaborations to ... What role will combination therapies play going forward into 2016? .... Venture Capital Funding Trends: BIO Analysis of Ten Years of Investment.
Oct 20, 2015 - companies and explore potential partnerships and business collaborations to ... What role will combination therapies play going forward into 2016? .... Venture Capital Funding Trends: BIO Analysis of Ten Years of Investment.
Tim Hsiau, University of California -Berkeley. William Kenealy ... James Carothers, University of Washington -. Seattle ... Wim Vermaas, Arizona State University.
Track 2. Track 3. Track 4. Track 5. Advanced Biofuels and Biorefinery ... Renewable Oil Feedstocks for the Pacific. Rim .... Roger Sedjo, Resources for the Future.
Aug 2, 2016 - information (e.g., social media and the general availability of health-related ..... 10 This sentiment was reiterated by US House of Representatives Committee on ... 98 of the top English-language websites on celiac disease, ...
and the well-paying jobs it supports.2 ... 2 Scientific American Worldview: A Global Biotechnology ..... http://www.manhattan-institute.org/html/fda_04.htm.
Nov 1, 2017 - protecting and promoting access to resources for comprehensive pain and addiction treatment. 3. STIMULATE RESEARCH & DEVELOPMENT (R&D) OF INNOVATIVE. TREATMENTS THAT EFFECTIVELY TREAT PAIN AND OPIOID. ADDICTION AND PREVENT ABUSE. ⢠In
makes positive contributions to global food production and food security. ... house gas emissions while lessening the need for insecticides and pesticides.
retention, reduced pesticide runoff, and reduced greenhouse gas emissions. New developments help American farmers produce crops that use water more effi-.
Mar 1, 2017 - nutritional ingredients as well as flavors and fragrances; and. ⢠enzymes, which are used in household cleaners, laundry detergents, and ... Biomaterials, Biochemicals, Industrial Enzymes), By Application (Bioenergy, Food & Feed. Addi
Nov 28, 2012 - considered to withdrawn from the public domain. In addition ... system, based on mutually agreed terms between the provider and user of ... property rights based on use of such resources, is the best mechanism to ensure.
May 9, 2016 - Clear from the aggressive CMS PR campaign in introducing the âmodelâ. ⸠Oncologists are ... Pressure to get the lower cost therapy, not necessarily the best therapy. â« Moving ... Cancer Clinics. Source: Medicare Data; Study in P
Nov 28, 2012 - a membership of more than 1,100 biotechnology companies, academic ... BIO's members are involved in the research and development of .... to create/add to, the patent application processing backlogs which will be.
May 9, 2016 - Proposed Structure: CMS identifies 4 strategies that the Agency is interested in ... Clear from the aggressive CMS PR campaign in introducing the âmodelâ ... Pressure to get the lower cost therapy, not necessarily the best.
